ADAM17 and hepatocellular carcinoma: They found that the treatment of HCC cell lines in vitro with lomofungin, an FDA-approved antibiotic compound, significantly decreased ADAM17 expression, increasing membrane MICA and thus, decreasing sMICA in culture media [213].